Exposure to topical apraclonidine in children with glaucoma

Journal of Glaucoma

Volumn 18, Issue 5, 2009, Pages 395-398

  Wright, Tarra M ^a   Freedman, Sharon F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apraclonidine; Congenital glaucoma; IOP; Safety

Indexed keywords

ACETAZOLAMIDE; ANTIBIOTIC AGENT; APRACLONIDINE; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CYCLOPLEGIC AGENT; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PREDNISOLONE; PROSTAGLANDIN DERIVATIVE; STEROID; TIMOLOL;

ADOLESCENT; ALLERGIC CONJUNCTIVITIS; ANESTHESIA; APHAKIA; ARTICLE; CHILD; CONGENITAL GLAUCOMA; DECREASED APPETITE; DEMOGRAPHY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GLAUCOMA SURGERY; HUMAN; INFANT; INTRAOCULAR PRESSURE; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PETERS ANOMALY; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; SECONDARY GLAUCOMA; SHORT COURSE THERAPY; STURGE WEBER SYNDROME; TRABECULOTOMY; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; APPETITE; CHILD; CHILD, PRESCHOOL; CLONIDINE; DRUG HYPERSENSITIVITY; FEMALE; GLAUCOMA; HUMANS; INFANT; INFANT, NEWBORN; INTRAOPERATIVE CARE; LETHARGY; MALE; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; TRABECULECTOMY;

EID: 68249108168     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31818624e5     Document Type: Article

References (13)

1. Roust BSS. (3H) para-aminoclonidine: a novel ligand which binds with high affinity to alpha-adrenergic receptors. Life Sci. 1979;25:769-774.
2. Kitazawa Y, Taniguchi T, Sugiyama K. Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy. Ophthalmic Surg. 1989; 20:49-52. (Pubitemid 19023086)
3. Threlkeld AB, Assalian AA, Allingham RR, et al. Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. Ophthalmic Surg Lasers. 1996;27:657-660. (Pubitemid 26269410)
4. Rosenberg LF, Krupin T, Ruderman J, et al. Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Ophthalmology. 1995; 102:1312-1318.
5. Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79:1098-1101.
6. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye. 2004;18:24-26. (Pubitemid 38180889)
7. Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112:2143. (Pubitemid 41720993)
8. Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255-256.
9. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J Aapos. 2001;5:281-284.
10. Chen PL, Hsiao CH, Chen JT, et al. Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination. Am J Ophthalmol. 2006;142: 469-474.
11. Bacal DA, Levy SR. The use of apraclonidine in the diagnosis of horner syndrome in pediatric patients. Arch Ophthalmol. 2004;122:276-279.
12. Watts P, Satterfield D, Lim MK. Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. J AAPOS. 2007;11:282-283. (Pubitemid 46899576)
13. Stewart PA, Hayakawa EM. Interendothelial junctional changes underlie the developmental "tightening" of the blood-brain barrier. Brain Res. 1987;429:271-281.